Bristol-Myers CEO Says Celgene Deal Not Defensive

The transcript discusses a major farmer deal involving Bristol Myers Squibb and Celgene, highlighting its strategic importance and potential for shareholder value. The speaker addresses shareholder concerns, emphasizing the deal's rationale and the company's history of successful transformations. The discussion covers challenges in the pharmaceutical market, including competition and patent issues, while focusing on innovation and the pipeline. The speaker also evaluates scientific claims and the impact on patient outcomes, clarifying the deal's non-defensive nature and future growth prospects.

How does the CEO plan to address shareholder questions and concerns about the deal?

What is the significance of the pipeline from Celgene for Bristol Myers Squibb?

In what ways does the merger aim to improve patient outcomes?